Aminolevulinic acid hydrochloride - Generic Drug Details

What are the generic drug sources for aminolevulinic acid hydrochloride and what is the scope of patent protection?

Aminolevulinic acid hydrochloride is the generic ingredient in three branded drugs marketed by Nxdc, Biofrontera, and Sun Pharm Inds Inc, and is included in three NDAs. There are thirteen patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Aminolevulinic acid hydrochloride has fifty-four patent family members in nineteen countries.

There are five drug master file entries for aminolevulinic acid hydrochloride. Four suppliers are listed for this compound.

Summary for aminolevulinic acid hydrochloride

International Patents:	54
US Patents:	13
Tradenames:	3
Applicants:	3
NDAs:	3
Drug Master File Entries:	5
Finished Product Suppliers / Packagers:	4
Raw Ingredient (Bulk) Api Vendors:	151
Clinical Trials:	110
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for aminolevulinic acid hydrochloride
What excipients (inactive ingredients) are in aminolevulinic acid hydrochloride?	aminolevulinic acid hydrochloride excipients list
DailyMed Link:	aminolevulinic acid hydrochloride at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for aminolevulinic acid hydrochloride

Dosage:

SOLUTION;TOPICAL

Constraining patent/regulatory exclusivity:

INCREASE IN THE APPROVED DOSAGE REGIMEN TO A MAXIMUM APPLICATION AREA OF 60 CM^2 IN TOTAL (CORRESPONDING TO THREE 2 GM TUBES)

Dosage:

GEL;TOPICAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for aminolevulinic acid hydrochloride

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of Pittsburgh Medical Center	PHASE2
NX Development Corp	PHASE2
StacheStrong Foundation	PHASE2

See all aminolevulinic acid hydrochloride clinical trials

Pharmacology for aminolevulinic acid hydrochloride

Drug Class	Optical Imaging Agent Porphyrin Precursor
Mechanism of Action	Fluorescence Contrast Activity

Medical Subject Heading (MeSH) Categories for aminolevulinic acid hydrochloride

Photosensitizing Agents

Anatomical Therapeutic Chemical (ATC) Classes for aminolevulinic acid hydrochloride

L01XD	Sensitizers used in photodynamic/radiation therapy
L01X	OTHER ANTINEOPLASTIC AGENTS
L01	ANTINEOPLASTIC AGENTS
L	Antineoplastic and immunomodulating agents

US Patents and Regulatory Information for aminolevulinic acid hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sun Pharm Inds Inc	LEVULAN	aminolevulinic acid hydrochloride	SOLUTION;TOPICAL	020965-001	Dec 3, 1999		RX	Yes	Yes
Sun Pharm Inds Inc	LEVULAN	aminolevulinic acid hydrochloride	SOLUTION;TOPICAL	020965-001	Dec 3, 1999		RX	Yes	Yes
Sun Pharm Inds Inc	LEVULAN	aminolevulinic acid hydrochloride	SOLUTION;TOPICAL	020965-001	Dec 3, 1999		RX	Yes	Yes

Expired US Patents for aminolevulinic acid hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Sun Pharm Inds Inc	LEVULAN	aminolevulinic acid hydrochloride	SOLUTION;TOPICAL	020965-001	Dec 3, 1999
Sun Pharm Inds Inc	LEVULAN	aminolevulinic acid hydrochloride	SOLUTION;TOPICAL	020965-001	Dec 3, 1999
Sun Pharm Inds Inc	LEVULAN	aminolevulinic acid hydrochloride	SOLUTION;TOPICAL	020965-001	Dec 3, 1999

International Patents for aminolevulinic acid hydrochloride

Country	Patent Number	Title	Estimated Expiration
World Intellectual Property Organization (WIPO)	2017066270
Japan	7382832
Canada	3029792	METHODES DE THERAPIE PHOTODYNAMIQUE (METHODS FOR PHOTODYNAMIC THERAPY)

Market Dynamics and Financial Trajectory for Aminolevulinic Acid Hydrochloride (ALA-HCl)

Last updated: July 27, 2025

---

Introduction

Aminolevulinic Acid Hydrochloride (ALA-HCl) is a pivotal compound in photodynamic therapy (PDT), prominently used for the treatment of dermatologic conditions, notably actinic keratosis, and is increasingly explored for oncological applications. Its unique properties as a precursor to protoporphyrin IX (PpIX), which accumulates selectively in abnormal cells, underpin its therapeutic efficacy. This article examines the comprehensive market dynamics, regulatory landscape, technological advancements, competitive environment, and financial outlook surrounding ALA-HCl.

---

Market Overview and Growth Drivers

The global pharmaceutical market for ALA-HCl hinges primarily on its role in PDT, a minimally invasive treatment modality gaining widespread acceptance due to its safety profile and efficacy. The market is segmented by application areas, including dermatology (actinic keratosis, field cancerization), oncology, and other emerging indications such as bacterial infections and cosmetic procedures.

Growing Prevalence of Target Conditions

The increasing incidence of skin cancers and precancerous lesions propels demand for ALA-HCl-based therapies. According to the Skin Cancer Foundation, over 3.3 million nonmelanoma skin cancers are diagnosed annually in the U.S., fuelling the need for effective PDT solutions [1]. Moreover, aging populations and heightened awareness about minimally invasive therapies bolster growth.

Technological Advancements

Innovations in formulation—such as cream and gel preparations, controlled-release systems, and combination therapies—improve drug delivery efficiency, patient compliance, and treatment outcomes. These innovations expand ALA-HCl's therapeutic window and facilitate its integration into clinical protocols.

Regulatory Approvals and Reimbursement Policies

Regulatory approvals from agencies like the FDA (U.S.) and EMA (Europe) validate ALA-HCl's safety and efficacy, fostering clinician confidence and patient access. Reimbursement policies in major markets directly influence adoption rates, especially in outpatient settings.

Emerging Indications and Research

Research exploring ALA-HCl for glioma, bladder cancer, and bacterial infections is expanding its application scope. Clinical trials reporting favorable outcomes drive investor interest and market expansion prospects.

---

Market Challenges

Despite positive growth drivers, market vibrancy faces notable hurdles:

• Pricing and Cost Constraints: High treatment costs and reimbursement variability impact penetration, especially in emerging markets.
• Competition from Alternative Therapies: Laser ablation, cryotherapy, and systemic medications offer competing treatment options.
• Limited Patent Life and Generic Entry: Patent expirations threaten exclusivity, prompting price erosion.
• Manufacturing Complexities: Ensuring consistent quality and stability during synthesis and formulation of ALA-HCl poses technical challenges.

---

Regulatory and Patent Landscape

Current patent supports monopolistic pricing and market exclusivity in key territories. Patent protection for specific formulations and manufacturing processes extends this window, but the imminent expiration of core patents could catalyze generic entries, intensifying price competition.

Regulatory frameworks mandate stringent quality controls and clinical trial data to support approvals. Countries with rising healthcare standards increasingly require comprehensive dossiers, impacting time-to-market and development costs.

---

Competitive Environment

Leading pharmaceutical companies investing in ALA-HCl include Cancer Therapy Network, DUSA Pharmaceuticals (with its flagship product, Levulan Kerastick), and emerging biotech firms exploring innovative delivery systems. Generic manufacturers are positioned to capitalize post-patent expiry, expanding access and driving price declines.

Partnerships with device manufacturers—such as laser and light source providers—are crucial to develop integrated therapeutic systems, augmenting treatment efficacy and market reach.

---

Financial Trajectory and Investment Outlook

Market Size and Revenue Estimates

The global PDT market, driven primarily by ALA-HCl and derivatives, was valued at approximately USD 556 million in 2021, with a compound annual growth rate (CAGR) estimated at 6.8% [2]. ALA-HCl sales constitute an estimated 65-70% of this segment, indicating significant revenue potential.

Forecasted Growth Patterns

Market forecasts suggest revenues for ALA-HCl will reach USD 1.1 billion by 2030, powered by expanding indications, technological advances, and increasing acceptance in global markets. Notably, Asia-Pacific exhibits the highest growth potential, due to rising healthcare expenditure and skin cancer prevalence.

Investment Trends

Venture capital investments in biotech firms exploring novel ALA-HCl formulations and applications underscore industry confidence. Companies leveraging synthetic biology for cost-efficient production and stability improvements attract strategic partnerships, bolstering the financial trajectory.

Pricing Dynamics

While initial high pricing due to patent protections supports margins, anticipated market entry of generics and increased competition will drive prices downward. Companies with early innovations and robust patent portfolios will benefit from sustained revenues until patent cliffs.

---

Impact of Market Dynamics on Financial Strategy

For pharmaceutical firms and investors, understanding the intricate balance between innovation, patent protection, regulatory influence, and market competition is crucial. Strategic investments in R&D to develop differentiated formulations, streamline manufacturing, and expand indications can capitalize on market growth while mitigating patent expiration risks.

Furthermore, engagement with policymakers and healthcare providers to establish favorable reimbursement frameworks is pivotal in ensuring sustained revenue streams.

---

Regulatory Pathways and Innovation Opportunities

Accelerated approval pathways, orphan drug designations, and compassionate use protocols facilitate faster market access for novel ALA-HCl formulations. Continual research into combination therapies, such as integrating ALA-HCl with immuno-oncology agents, could open new revenue streams and extend the commercial lifespan of existing formulations.

---

Conclusion and Future Outlook

Aminolevulinic Acid Hydrochloride is positioned as a critical component in the expanding landscape of photodynamic and targeted therapies. Its market dynamics are shaped by technological advances, regulatory developments, healthcare trends, and competitive pressures. Financial trajectories indicate sustained growth, especially in dermatology and oncology applications, with notable upside in emerging markets.

While patent expiries and competition pose challenges, strategic investments in innovation, formulation improvements, and geographic expansion will underpin long-term profitability. Stakeholders must monitor regulatory changes, patent landscapes, and clinical research to optimize decision-making in this evolving market.

---

Key Takeaways

• Market Expansion: Growing prevalence of skin cancers and minimally invasive therapies propel demand for ALA-HCl globally.
• Innovation-Driven Growth: Formulation innovations and expanding indications create competitive advantages, driving revenue growth.
• Patent and Competition Risks: Patent expiries and generics will pressure prices; strategic IP management is crucial.
• Regulatory and Reimbursement Factors: Regulatory approvals and favorable reimbursement policies are vital for market penetration.
• Emerging Markets: Asia-Pacific and other developing regions offer significant growth opportunities due to rising healthcare expenditures.

---

FAQs

1. What are the primary medical applications of aminolevulinic acid hydrochloride?
   ALA-HCl is mainly utilized in photodynamic therapy (PDT) for actinic keratosis, superficial basal cell carcinoma, and other dermatologic conditions. Emerging research explores its potential in oncology and infectious disease treatments.

2. How does patent patent expiry impact the ALA-HCl market?
   Patent expiration introduces generic manufacturers, increasing competition and reducing prices. This shift can erode profit margins but also broadens access, potentially expanding the market size.

3. What technological innovations are shaping the future of ALA-HCl therapies?
   Innovations include controlled-release formulations, combination delivery systems, and integration with light-emitting devices, enhancing specificity, efficacy, and patient compliance.

4. Which regions have the highest growth potential for ALA-HCl?
   North America and Europe exhibit mature markets, while Asia-Pacific offers significant growth due to increasing healthcare investments, disease prevalence, and evolving treatment standards.

5. What are the key considerations for investors in the ALA-HCl pharmaceutical market?
   Investors should evaluate patent landscapes, R&D pipelines, regulatory pathways, market penetration strategies, and collaborations with device manufacturers to assess growth potential and mitigate risks.

---

Sources

[1] Skin Cancer Foundation. "Nonmelanoma Skin Cancer Facts & Statistics." (2022).
[2] MarketsandMarkets. "Photodynamic Therapy Market by Application, End User, and Region." 2021.